Oncogenic activation of NF-kappaB

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Nuclear factor kappa B (NF-kappaB) signaling is crucial for normal B lymphocyte function but is constitutively activated in lymphomas.
• Genetic aberrations in lymphomas often target the CARD11, MALT1, or BCL10 complex, leading to aberrant NF-kappaB activation.
• Constitutive NF-kappaB activation is also observed in multiple myeloma and epithelial cancers through various mechanisms.

Purpose of the Study:

• To review the pathogenetic role of NF-kappaB signaling in diverse cancer types.
• To highlight the mechanisms of NF-kappaB dysregulation in lymphomas, multiple myeloma, and epithelial cancers.
• To establish the therapeutic rationale for targeting NF-kappaB in cancer treatment.

Main Methods:

• Review of genetic evidence linking NF-kappaB signaling to cancer pathogenesis.
• Analysis of signaling pathways involved in B-cell lymphomas and multiple myeloma.
• Examination of NF-kappaB activation mechanisms in epithelial cancers.

Main Results:

• Genetic lesions in lymphomas lead to constitutive NF-kappaB activation via alterations in key signaling intermediates.
• Multiple myeloma exhibits sustained NF-kappaB activation through NIK stabilization.
• Oncogenic abnormalities in epithelial cancers activate NF-kappaB through unconventional pathways.

Conclusions:

• Constitutive NF-kappaB signaling is a common pathogenetic mechanism across various cancers.
• Inhibition of aberrant NF-kappaB signaling induces apoptosis in cancer cells.
• Targeting the NF-kappaB pathway presents a promising therapeutic strategy for cancer treatment.